Alzamend Neuro Files 8-K with Corporate Updates
Ticker: ALZN · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financials
Related Tickers: ALZN
TL;DR
ALZN filed an 8-K on 10/14/25 for corporate updates & financials.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on October 14, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibits. The company, incorporated in Delaware, is in the Pharmaceutical Preparations industry and is headquartered in Atlanta, GA.
Why It Matters
This filing indicates significant corporate actions and the submission of financial information, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- October 14, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Atlanta, GA (location) — Principal Executive Office
FAQ
What specific amendments were made to Alzamend Neuro, Inc.'s Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information.
What financial statements and exhibits are being filed with this 8-K?
The filing states that Financial Statements and Exhibits are being filed, but the specific content of these documents is not detailed in the provided text.
When was Alzamend Neuro, Inc. incorporated or organized?
The filing does not explicitly state the incorporation date, but it confirms the company is incorporated in Delaware.
What is Alzamend Neuro, Inc.'s Standard Industrial Classification (SIC) code?
Alzamend Neuro, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the business address of Alzamend Neuro, Inc.?
The business address is 480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-10-14 16:51:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
Filing Documents
- b10142528k.htm (8-K) — 25KB
- ex3_1.htm (EX-3.1) — 8KB
- ex3_2.htm (EX-3.2) — 8KB
- ex31-001.jpg (GRAPHIC) — 46KB
- ex31-002.jpg (GRAPHIC) — 173KB
- ex31-003.jpg (GRAPHIC) — 51KB
- ex32-001.jpg (GRAPHIC) — 46KB
- ex32-002.jpg (GRAPHIC) — 186KB
- ex32-003.jpg (GRAPHIC) — 37KB
- 0001214659-25-014950.txt ( ) — 959KB
- alzn-20251014.xsd (EX-101.SCH) — 3KB
- alzn-20251014_lab.xml (EX-101.LAB) — 33KB
- alzn-20251014_pre.xml (EX-101.PRE) — 22KB
- b10142528k_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation; Change in Fiscal Year. On October 14, 2025, Alzamend Neuro , Inc., a Delaware corporation (the " Company "), filed Certificates of Elimination (collectively, the " Certificates of Elimination ") with the Secretary of State of the State of Delaware with respect to the Company's Series B convertible preferred stock and Series C convertible preferred stock (collectively, the " Preferred Stock "), which, effective upon filing, eliminated from the Company's Certificate of Incorporation, as amended, all matters set forth in the Certificates of Designations for the Preferred Stock. Copies of the Certificates of Elimination for the Preferred Stock are attached as Exhibits 3.1 and 3.2 to this report and are incorporated herein by reference.
01 Financial Statements And Exhibits
Item 9.01 Financial Statements And Exhibits (d) Exhibits: Exhibit No. Description 3.1 Certificate of Elimination of the Series B convertible preferred stock, filed with the Delaware Secretary of State on October 14, 2025. 3.2 Certificate of Elimination of the Series C convertible preferred stock, filed with the Delaware Secretary of State on October 14, 2025. 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: October 14, 2025 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel